Regulatory timeline
Federal safety actions on COVID-19 vaccines, in order: signals, pauses, recommendations, warnings, label changes, restrictions and withdrawals — with whether each is still current, was superseded, or was a signal later evaluation did not confirm. A preliminary signal is never shown as an established finding.
Topic: All · Myocarditis and pericarditis · Blood clots and thrombosis with thrombocytopenia (TTS) · Stroke · Guillain-Barré syndrome
Agency: FDA · CDC
-
CDC and FDA recommend pausing the Janssen (J&J) vaccine after rare clots with low platelets
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: All recipients
What changed: Use paused while six reported cases of cerebral venous sinus thrombosis with low platelets were reviewed.
CDC and FDA recommended pausing the vaccine “out of an abundance of caution” while reviewing six U.S. reports of cerebral venous sinus thrombosis with thrombocytopenia among more than 6.8 million doses.
A pause to investigate is not a finding that the vaccine caused the events.
-
FDA and CDC lift the Janssen pause and add a clotting warning
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: All recipients
What changed: Use resumed; fact sheets updated with information on the risk of thrombosis with thrombocytopenia.
After two ACIP meetings and a safety review, the agencies lifted the pause and added information about the rare clotting risk to the vaccine's fact sheets.
Superseded by the May 2022 restriction.
Later: FDA restricted the vaccine's use on May 5, 2022.
-
CDC adopts ACIP's preference for mRNA vaccines over the Janssen vaccine
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: Adults
What changed: Recommendation changed to prefer mRNA vaccines, citing thrombosis with thrombocytopenia syndrome.
ACIP recommended mRNA vaccines over the Janssen vaccine for adults, citing the risk of thrombosis with thrombocytopenia syndrome; CDC adopted the recommendation.
Superseded by the 2022 FDA restriction.
Later: FDA restricted the vaccine's use on May 5, 2022.
-
FDA limits use of the Janssen (J&J) COVID-19 vaccine because of thrombosis with thrombocytopenia syndrome
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: Adults 18 and older
What changed: Authorized use narrowed to adults without access to, or clinically unable to receive, other COVID-19 vaccines, or who would otherwise not be vaccinated.
FDA limited authorized use of the Janssen vaccine to adults for whom other COVID-19 vaccines were not accessible or clinically appropriate, or who would otherwise not be vaccinated, after determining that the risk of thrombosis with thrombocytopenia syndrome (rare, potentially life-threatening clots with low platelets, with onset about one to two weeks after vaccination) warranted the restriction.
The Janssen vaccine is no longer authorized for use in the United States; this record documents the 2022 regulatory finding.
Later: FDA revoked the Janssen EUA at the company's request on June 1, 2023.
-
FDA revokes the Janssen vaccine's emergency authorization at the company's request
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: All
What changed: Emergency use authorization revoked; the vaccine is no longer available in the United States.
Janssen asked FDA to withdraw the authorization because the last U.S. government lots had expired, there was no demand, and it did not intend to update the vaccine; FDA revoked it.
The stated reasons were commercial and supply-related, not a new safety finding.
Thread: janssen tts
- Pause — CDC and FDA recommend pausing the Janssen (J&J) vaccine after rare clots with low platelets Lifted
- Warning — FDA and CDC lift the Janssen pause and add a clotting warning Superseded
- Recommendation — CDC adopts ACIP's preference for mRNA vaccines over the Janssen vaccine Superseded
- Restriction — FDA limits use of the Janssen (J&J) COVID-19 vaccine because of thrombosis with thrombocytopenia syndrome Superseded
- Withdrawal — FDA revokes the Janssen vaccine's emergency authorization at the company's request Withdrawn